Jenscare Biotechnology Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
225
- Stock Symbol
-
09877
- Investments
-
1
- Share Price
-
$0.80
- (As of Friday Closing)
Jenscare Biotechnology General Information
Description
Jenscare Scientific Co Ltd is engaged in the manufacturing, research, and development of medical devices. The company develops interventional products for the treatment of structural heart disease. The company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure. Geographically, the company generates the majority of its revenue from the Chinese mainland.
Contact Information
Website
www.jenscare.comCorporate Office
- Block 5, B Area No. 777 Binhai 4th Road
- Hangzhou Bay New District
- Ningbo, Zhejiang
- China
Corporate Office
- Block 5, B Area No. 777 Binhai 4th Road
- Hangzhou Bay New District
- Ningbo, Zhejiang
- China
Jenscare Biotechnology Stock Performance
As of 13-Nov-2026, Jenscare Biotechnology’s stock price is $0.80. Its current market cap is $336M with 417M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.80 | $0.79 | $0.74 - $1.35 | $336M | 417M | 50K | -$0.05 |
Jenscare Biotechnology Financials Summary
As of 30-Jun-2026, Jenscare Biotechnology has a trailing 12-month revenue of $20.2M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 315,329 | 424,481 | 66,764 | 1,084,199 |
| Revenue | 20,192 | 12,597 | 0 | 0 |
| EBITDA | (19,675) | (37,755) | (25,636) | (54,590) |
| Net Income | (21,487) | (37,716) | (24,738) | (52,543) |
| Total Assets | 123,880 | 128,094 | 140,760 | 187,215 |
| Total Debt | 5,842 | 6,769 | 8,824 | 6,218 |
Jenscare Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Jenscare Biotechnology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Jenscare Biotechnology Patents
Jenscare Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-243805-S | Prosthetic heart valve | Active | 30-Jul-2025 | ||
| JP-2026096903-A | Heart valve prosthesis fixed by the interventricular septum | Pending | 03-Dec-2024 | ||
| AU-2025200571-B1 | Heart valve prosthesis fixed through interventricular septum | Active | 03-Dec-2024 | ||
| WO-2023246902-A1 | Prosthetic valve | Inactive | 24-Jun-2022 | ||
| WO-2023169376-A1 | Forming device for repairing valve | Inactive | 07-Mar-2022 | A61F2/2445 |
Jenscare Biotechnology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Jenscare Biotechnology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Jenscare Biotechnology Investments (1)
Jenscare Biotechnology’s most recent deal was a Secondary Transaction - Private with Huayi Shengjie. The deal was made on 07-May-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Huayi Shengjie | 07-May-2021 | Secondary Transaction - Private | Therapeutic Devices |
Jenscare Biotechnology ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Devices
Subindustry
Rank
Percentile
Jenscare Biotechnology Exits (1)
Jenscare Biotechnology’s most recent exit was on 07-May-2021 from Huayi Shengjie. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Huayi Shengjie | 07-May-2021 | Completed |
|
Jenscare Biotechnology FAQs
-
When was Jenscare Biotechnology founded?
Jenscare Biotechnology was founded in 2011.
-
Where is Jenscare Biotechnology headquartered?
Jenscare Biotechnology is headquartered in Ningbo, China.
-
What is the size of Jenscare Biotechnology?
Jenscare Biotechnology has 225 total employees.
-
What industry is Jenscare Biotechnology in?
Jenscare Biotechnology’s primary industry is Therapeutic Devices.
-
Is Jenscare Biotechnology a private or public company?
Jenscare Biotechnology is a Public company.
-
What is Jenscare Biotechnology’s stock symbol?
The ticker symbol for Jenscare Biotechnology is 09877.
-
What is the current stock price of Jenscare Biotechnology?
As of 13-Nov-2026 the stock price of Jenscare Biotechnology is $0.80.
-
What is the current market cap of Jenscare Biotechnology?
The current market capitalization of Jenscare Biotechnology is $336M.
-
What is Jenscare Biotechnology’s current revenue?
The trailing twelve month revenue for Jenscare Biotechnology is $20.2M.
-
What is Jenscare Biotechnology’s annual earnings per share (EPS)?
Jenscare Biotechnology’s EPS for 12 months was -$0.05.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
